Trial reportArthritis research & therapy2007
A pilot study of IL-1 inhibition by anakinra in acute gout.
Trial report in Arthritis research & therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 281 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
281 citing papers in PubMed, 5 syntheses or guidelines pooled it, 721 citations in OpenAlex.
- Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review.Arthritis research & therapy · 2023Pooled it
- Interleukin-1 blockade treatment decreasing cardiovascular risk.Clinical cardiology · 2019Pooled it
- [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].Zeitschrift fur Rheumatologie · 2016Guideline
- Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.Clinical rheumatology · 2016Pooled it
- 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.Arthritis care & research · 2012Guideline
- Trial
- Trial
- Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.Arthritis research & therapy · 2013Trial
- Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes.Arthritis and rheumatism · 2012Trial
- The 100 top-cited articles in gout: A bibliometric analysis.Medicine · 2026Article
- Post-transplant metabolic dysregulation: Insights and implications for kidney graft survival.World journal of nephrology · 2026Review
- Get OUT: Factors Associated With a Longer Length of Stay in Patients Admitted With an Acute Gout Flare, and the Effects of Anakinra on Length of Stay.International journal of rheumatic diseases · 2025Article
- Review
- Risk of incident gout in rheumatoid arthritis from a nationwide cohort study in South Korea.Scientific reports · 2025Article
- Review
- Hyperuricemia-induced complications: dysfunctional macrophages serve as a potential bridge.Frontiers in immunology · 2025Review
- Zinc homeostasis regulates caspase activity and inflammasome activation.PLoS pathogens · 2024Article
- Review
- Managing Gout in Patients with Metabolic Syndrome.Drugs & aging · 2024Review
- Mechanistic insights from inflammasome structures.Nature reviews. Immunology · 2024Review
221 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monosodium urate crystals stimulate monocytes and macrophages to release IL-1beta through the NALP3 component of the inflammasome. The effectiveness of IL-1 inhibition in hereditary autoinflammatory syndromes with mutations in the NALP3 protein suggested that IL-1 inhibition might also be effective in relieving the inflammatory manifestations of acute gout. The effectiveness of IL-1 inhibition was first evaluated in a mouse model of monosodium urate crystal-induced inflammation. IL-1 inhibition prevented peritoneal neutrophil accumulation but TNF blockade had no effect. Based on these findings, we performed a pilot, open-labeled study (trial registration number ISRCTN10862635) in 10 patients with gout who could not tolerate or had failed standard antiinflammatory therapies. All patients received 100 mg anakinra daily for 3 days. All 10 patients with acute gout responded rapidly to anakinra. No adverse effects were observed. IL-1 blockade appears to be an effective therapy for acute gouty arthritis. The clinical findings need to be confirmed in a controlled study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.